Question 1

What is Amplia Therapeutics?

Accepted Answer

Amplia Therapeutics is a Company.

Question 2

How often does Amplia Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was Amplia Therapeutics first tracked by NewsDesk?

Accepted Answer

First tracked on May 09, 2026.

Question 4

When was Amplia Therapeutics last mentioned in news?

Accepted Answer

Last active on May 09, 2026.

Question 5

What is Amplia Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Amplia Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Amplia Therapeutics?

Accepted Answer

Amplia Therapeutics and ANZGOG Ovarian Cancer Study (May 09, 2026, 8 articles).

Question 8

How did the "Amplia Therapeutics and ANZGOG Ovarian Cancer Study" event impact Amplia Therapeutics?

Accepted Answer

Amplia Therapeutics is the developer of narmafotinib and has entered into an agreement with Australia New Zealand Gynaecological Oncology Group (ANZGOG) to conduct a clinical study in ovarian cancer. This study broadens the clinical utility of its FAK inhibitor program.

Question 9

How is this data collected?

Accepted Answer

NewsDesk aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.